A new way to detect faulty TDP-43 in MND
Related topics
Researchers from the University of Aberdeen and University of Edinburgh tested a new tool called an aptamer for detecting faulty TDP-43, a protein linked to MND. In postmortem brain tissue, it detected smaller TDP-43 clumps than antibody-based methods and detected faulty protein in samples from people with MND but not healthy controls. The findings suggest the tool could help study earlier disease changes, but it is not yet a diagnostic test or treatment.
Why this matters
The aptamer may help researchers detect and measure faulty TDP-43 more sensitively in tissue. If future studies confirm that faulty TDP-43 in the cell nucleus is an early disease sign, the approach could eventually support earlier diagnosis or research into disease progression. This work does not currently change treatment for people living with MND.
Limitations and context
The study used postmortem brain tissue from 24 people with MND and healthy controls, rather than testing people during life. The findings were reported through an organisational research blog, not directly from the primary paper in the supplied source. Whether the aptamer works in living patients, biological fluids, or routine diagnosis remains to be established. Its potential clinical benefits are therefore unconfirmed.